Patient Resources

Physicians (USA)
Physicians (Intl)
WM Workshops
WM Summits
Bing Ctr for WM
Contact Us

Waldenström's Macroglobulinemia (WM, also known as lymphoplasmacytic lymphoma) is cancer involving a subtype of white blood cells called lymphocytes. The main attributing antibody is IgM. It is a type of lymphoproliferative disease, and shares clinical characteristics with the indolent non-Hodgkin lymphomas. It is named after the Swedish physician Jan Gosta Waldenström, who first identified the condition in 1944.


The Waldenström's Macroglobulinemia Clinical Trials Group is comprised of over 20 major cancer centers around the world. Our mission is to maintain active clinical trials year round in an effort to constantly improve our understanding and continue to offer patients the most effective treatments for Waldenström's macroglobulinemia. By maintaining an extensive contingent of collaborating centers, we hope to be better able to enroll patients in our trials without delay. Not only does the WMCTG allow more convenient patient access to treatment, but will also facilitate completion of clinical trials in a more timely manner.

Latest WMCTG News

4th International Patient & Physician Summit, March 11-14, 2011, Orlando, Florida, USA.

Learn more at

The Seventh International Workshop on Waldenström's Macroglobulinemia was held on August 22-26, 2012, at the Hyatt Regency Hotel, Newport, Rhode Island.

Learn more at

Additional Resources

More information on WM and clinical trials is available at the following websites.

Copyright © 2009 Waldenström's Macroglobulinemia Clinical Trials Group. All rights reserved.

Hosting provided by Interactive E-ware